Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Janusmed Sex and Gender

News

New guidance aims to increase understanding of sex and gender as modifier of chronic disease
A review in Lancet explore the influences of sex and gender as modifiers of the major causes of death and morbidity. It aims to guide clinicians and researchers to consider sex and gender in their approach to diagnosis, prevention, and treatment of diseases, as a necessary step towards precision medicine.
09/22/2020

Consideration of sex now required by British Journal of Pharmacology
A new themed issue from British Journal of Pharmacology writes about the importance of sex differences in pharmacology research. A new journal policy recommends that all studies submitted for publication in the journal must consider sex as an experimental variable. Read the issue here.
11/21/2019

Sex differences in cancer risk and survival
A Swedish thesis have analysed sex differences in cancer risk and survival over time. Women's better survival in non-small cell lung cancer indicates sex differences in tumor biology. Women’s poorer survival in bladder cancer was restricted to those with muscle invasive bladder cancer, indicating differences in clinical management and treatment of men and women with muscle invasive tumors. The thesis also showed that the excess cancer risk in men is explained by body height.
12/06/2019

Read more news here!

Janusmed Sex & Gender is a knowledge bank with structured information on sex and gender aspects on drug treatment. The information is aimed towards healthcare personal. It is possible to search on generic names in English and trade names of drug products on the Swedish market. For detailed information on how to search, click on Search help in the blue search field. The purpose of the web site is to improve drug treatment by providing information on whether drug choice or drug dosing need to consider the patient's sex.

Please note that Janusmed Sex & Gender does not include information on teratogenic effects or compatibility with breast feeding. For this information, please consult the databases Janusmed Drugs and Birth Defects and Janusmed Drugs and Breastfeeding, respectively (in Swedish).

The Health and Medical Care Administration at Region Stockholm is responsible for the web site. The work is done in collaboration between the Drug Therapeutic Committee in Region Stockholm, Department of Clinical Pharmacology, Karolinska University Hospital and Centre for Gender Medicine, Karolinska Institutet.

A-Z list

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z